|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
blocks opioid receptors
|
|
gptkbp:appointed_by
|
oral tablet
injectable solution
|
|
gptkbp:approves
|
gptkb:1984
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Vivitrol
Depade
Re Via
|
|
gptkbp:clinical_trial
|
alcohol use disorder
opioid use disorder
|
|
gptkbp:contraindication
|
opioid use
acute opioid withdrawal
|
|
gptkbp:developed_by
|
gptkb:Endo_Pharmaceuticals
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
extended-release
immediate-release
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Naltrexone
|
|
gptkbp:ingredients
|
C20 H23 N3 O2
|
|
gptkbp:interacts_with
|
gptkb:buprenorphine
gptkb:naltrexone
opioids
|
|
gptkbp:is_atype_of
|
N07 B B04
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_used_for
|
alcohol dependence
opioid dependence
|
|
gptkbp:lifespan
|
4 hours
|
|
gptkbp:manager
|
subcutaneous
intramuscular
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:research_areas
|
mental health
substance use disorder
addiction treatment
pain management
pharmacotherapy
neuropharmacology
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
|
|
gptkbp:traded_on
|
gptkb:Vivitrol
Re Via
|
|
gptkbp:type_of
|
16595-80-5
|
|
gptkbp:bfsParent
|
gptkb:Searle_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|